{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T08:35:19Z","timestamp":1769243719474,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T00:00:00Z","timestamp":1513814400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1038\/s41409-017-0032-1","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T12:40:51Z","timestamp":1513341651000},"page":"366-370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma"],"prefix":"10.1038","volume":"53","author":[{"given":"Jacopo","family":"Mariotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raynier","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Furst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2846-9428","authenticated-orcid":false,"given":"Jean","family":"El Cheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Sarina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Granata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Faucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Harbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucio","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre Jean","family":"Weiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3755-4889","authenticated-orcid":false,"given":"Christian","family":"Chabannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamel","family":"Mokart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Mineri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6239-7387","authenticated-orcid":false,"given":"Luca","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,21]]},"reference":[{"key":"32_CR1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s11899-011-0091-0","volume":"6","author":"B Tresckow von","year":"2011","unstructured":"von Tresckow B, Engert A. The role of autologous transplantation in Hodgkin lymphoma. Curr Hematol Malig Rep. 2011;6:172\u20139.","journal-title":"Curr Hematol Malig Rep"},{"key":"32_CR2","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.bbmt.2013.09.018","volume":"19","author":"T Hahn","year":"2013","unstructured":"Hahn T, McCarthy PL, Carreras J, Zhang MJ, Lazarus HM, Laport GG, et al. Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma. Biol Blood Marrow Transplant. 2013;19:1740\u20134.","journal-title":"Biol Blood Marrow Transplant"},{"key":"32_CR3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdi119","volume":"16","author":"A Sureda","year":"2005","unstructured":"Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse. Ann Oncol. 2005;16:625\u201333.","journal-title":"Ann Oncol"},{"key":"32_CR4","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30:2183\u20139.","journal-title":"J Clin Oncol"},{"key":"32_CR5","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128:1562\u20136.","journal-title":"Blood"},{"key":"32_CR6","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1200\/JCO.2007.15.5887","volume":"26","author":"F Morschhauser","year":"2008","unstructured":"Morschhauser F, Brice P, Ferm\u00e9 C, Divin\u00e9 M, Salles G, Bouabdallah R, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse\/refractory Hodgkin\u2019s lymphoma: results of the prospective multicenter H96 trial by the GELA\/SFGM study group. J Clin Oncol. 2008;26:5980\u20137.","journal-title":"J Clin Oncol"},{"key":"32_CR7","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2000.18.23.3918","volume":"18","author":"AM Carella","year":"2000","unstructured":"Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2000;18:3918\u201324.","journal-title":"J Clin Oncol"},{"key":"32_CR8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/bmt.2014.304","volume":"50","author":"L Castagna","year":"2015","unstructured":"Castagna L, Crocchiolo R, Giordano L, Bramanti S, Carlo-Stella C, Sarina B, et al. High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. Bone Marrow Transplant. 2015;50:499\u2013504.","journal-title":"Bone Marrow Transplant"},{"key":"32_CR9","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/bmt.2013.166","volume":"49","author":"A Raiola","year":"2014","unstructured":"Raiola A, Dominietto A, Varaldo R, Ghiso A, Galaverna F, Bramanti S, et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2014;49:190\u20134.","journal-title":"Bone Marrow Transplant"},{"key":"32_CR10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/bmt.2016.348","volume":"52","author":"L Castagna","year":"2017","unstructured":"Castagna L, Bramanti S, Devillier R, Sarina B, Crocchiolo R, Furst S, et al. Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. Bone Marrow Transplant. 2017;52:683\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"32_CR11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bmt.1705081","volume":"36","author":"JA Gutman","year":"2005","unstructured":"Gutman JA, Bearman SI, Nieto Y, Sweetenham JW, Jones RB, Shpall EJ, et al. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study. Bone Marrow Transplant. 2005;36:443\u201351.","journal-title":"Bone Marrow Transplant"},{"key":"32_CR12","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/leu.2014.194","volume":"29","author":"P Satwani","year":"2015","unstructured":"Satwani P, Jin Z, Martin PL, Bhatia M, Garvin JH, George D, et al. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia. 2015;29:448\u201355.","journal-title":"Leukemia"},{"key":"32_CR13","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3324\/haematol.2011.056051","volume":"97","author":"R Devillier","year":"2012","unstructured":"Devillier R, Coso D, Castagna L, Brenot Rossi I, Anastasia A, Chiti A, et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and\/or refractory Hodgkin\u2019s lymphoma responding to prior salvage therapy. Haematologica. 2012;97:1073\u20132079.","journal-title":"Haematologica"},{"key":"32_CR14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","volume":"16","author":"AJ Moskowitz","year":"2015","unstructured":"Moskowitz AJ, Sch\u00f6der H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16:284\u201392.","journal-title":"Lancet Oncol"},{"key":"32_CR15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372:311\u20139.","journal-title":"N Engl J Med"},{"key":"32_CR16","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","volume":"31","author":"A Bashey","year":"2013","unstructured":"Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31:1310\u20136.","journal-title":"J Clin Oncol"},{"key":"32_CR17","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","volume":"125","author":"SR McCurdy","year":"2015","unstructured":"McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bola\u00f1os-Meade J, Rosner GL, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125:3024\u201331.","journal-title":"Blood"},{"key":"32_CR18","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3324\/haematol.2012.072090","volume":"98","author":"E Neste Van Den","year":"2013","unstructured":"Van Den Neste E, Casasnovas O, Andr\u00e9 M, Touati M, Senecal D, Edeline V, et al. Classical Hodgkin\u2019s lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica. 2013;98:1185\u201395.","journal-title":"Haematologica"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-017-0032-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-017-0032-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-017-0032-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:10:57Z","timestamp":1684617057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-017-0032-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,21]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["32"],"URL":"https:\/\/doi.org\/10.1038\/s41409-017-0032-1","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,21]]}}}